The final, formatted version of the article will be published soon.
ORIGINAL RESEARCH article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 15 - 2024 |
doi: 10.3389/fimmu.2024.1422784
This article is part of the Research Topic Frontier Developments in Immunotherapy for Hepatocellular Carcinoma View all articles
Safety and efficacy of DEB-TACE in combination with lenvatinib and camrelizumab for the treatment of unresectable hepatocellular carcinoma (uHCC): A two-centre retrospective study
Provisionally accepted
Xuexian Zhang
1
Ruidong Wang
2
Yuhan Ding
3*
Qingwei Li
1*
Feng Xiong
1*
hong Ren
2*
Wei Li
1*
Jun Zhang
1*- 1 Jingmen People’s Hospital, Jingmen, China
- 2 Qujing Second People’s Hospital, Qujing, Yunnan Province, China
- 3 Jingmen Center Hospital, Jingmen, China
The purpose of this study was to compare the safety and efficacy of drug-eluting bead (DEB) transarterial chemoembolization combined with lenvatinib and camrelizumab (DEB-TACE-Len-C) and DEB-TACE-Len for the treatment of unresectable hepatocellular carcinoma (uHCC).Methods: This retrospective study consecutively included uHCC patients who underwent DEB-TACE-Len-C or DEB-TACE-Len treatment at our hospital and Qujing Second People's Hospital from April 2020 to April 2022. In total, 85 patients were enrolled. There were 42 patients in the DEB-TACE-Len-C group and 43 patients in the DEB-TACE-Len group. The disease control rate (DCR), objective response rate (ORR), overall survival (OS), progression-free survival (PFS), and adverse events (AEs) were compared between the two groups, and the factors influencing OS and PFS were analysed.
Keywords: Drug-eluting beads, Transarterial chemoembolization, Lenvatinib, camrelizumab, Unresectable hepatocellular carcinoma, Treatment, Safety, efficacy
Received: 24 Apr 2024; Accepted: 03 Oct 2024.
Copyright: © 2024 Zhang, Wang, Ding, Li, Xiong, Ren, Li and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Yuhan Ding, Jingmen Center Hospital, Jingmen, China
Qingwei Li, Jingmen People’s Hospital, Jingmen, China
Feng Xiong, Jingmen People’s Hospital, Jingmen, China
hong Ren, Qujing Second People’s Hospital, Qujing, Yunnan Province, China
Wei Li, Jingmen People’s Hospital, Jingmen, China
Jun Zhang, Jingmen People’s Hospital, Jingmen, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.